What Treatment Codes Conceal
In an adaptive trial, an interim review may need information separated by randomized arm. A code such as A or B can preserve that separation while concealing which arm received the investigational treatment and which received the comparator. This is useful only if the code-to-treatment mapping is protected: the letters alone do not guarantee that reviewers remain unaware of treatment identity.
The important distinction is between knowing which records belong together and knowing what treatment those records represent. A reviewer who sees separate summaries for A and B can compare their outcomes, sample sizes, or other prespecified summaries. The reviewer may therefore see a pattern suggestive of a treatment difference, even without knowing which named treatment corresponds to the pattern.
For example, suppose a two-arm trial assigns participants to the investigational treatment or control. The trial may store each participant’s allocation under a code and provide an authorized interim reviewer with separate summaries labelled A and B. The reviewer can distinguish the two sets of records, but—if the mapping is genuinely withheld—cannot tell from the labels alone which is the investigational treatment.
This is not the same as concealing all comparative information. Separate summaries can make differences visible. Nor does it guarantee that the reviewer cannot infer identity from outside information, such as a distinctive adverse-event pattern or knowledge of a treatment’s expected effects. Masking is an operational arrangement that must be maintained, not a property conferred by choosing letters.
What Can Be Learned From Coded Summaries?
Consider an outcome measured in the same units in both arms, with larger values defined in advance as better. If the coded summaries report mean outcomes \(\bar{x}_A\) and \(\bar{x}_B\), a reviewer can calculate the coded contrast \(\bar{x}_A-\bar{x}_B\). That contrast describes A relative to B, but its sign does not say whether the investigational treatment is better or worse unless the reviewer also knows the code mapping.
The same caution applies to quantities beyond means. A reviewer can see which coded arm has a larger event rate, a smaller observed variability, or more accrued participants if those summaries are provided. The reviewer should describe such results using the codes, not substitute treatment names based on a guess. A coded comparison may still be informative for a decision specified to depend on those summaries; its suitability depends on the decision rule and the trial’s prespecified safeguards.
Worked Example: Reading a Coded Mean Difference
Hypothetical data. At an interim review, coded arm A has 40 participants and a mean outcome of 8.2 units; coded arm B has 38 participants and a mean outcome of 8.0 units. Higher values are better. The treatment mapping is not available to the review group.
The coded difference, defined as A minus B, is:
Thus A’s observed mean is 0.2 units higher than B’s observed mean. Equivalently, the difference defined as B minus A is \(8.0-8.2=-0.2\) units. These are two ways to express the same comparison. The summaries do not establish that the investigational treatment has the higher mean, because the mapping of A and B to treatment identities is withheld. They also do not, by themselves, establish that the observed difference is a reliable estimate of a treatment effect.
There is a simple mathematical reason why a code swap changes the direction of a contrast but not its magnitude. If A and B are exchanged, the new A-minus-B difference is \(\bar{x}_B-\bar{x}_A\), which is the negative of the original difference. Taking absolute values removes that sign.
This label-swap property has limits. It concerns the arithmetic of a contrast when the two labels are exchanged; it does not prove that an adaptation rule is appropriate or that a trial’s error rates are controlled. Decisions based on coded summaries still require a defined rule, and the trial’s design should account for how interim information can influence later conduct and final analyses.
Worked Example: Comparing Coded Event Rates
Hypothetical data. Suppose the interim report gives 9 events among 60 participants in A and 12 events among 60 participants in B. Assume the event is undesirable and that the report uses the number of events divided by the number of participants as each observed event rate.
For A, the observed rate is \(9/60=0.15\), or 15%. For B, it is \(12/60=0.20\), or 20%. The coded difference, A minus B, is:
A’s observed event rate is 5 percentage points lower than B’s. Since the event is undesirable, that is an observed coded-arm pattern in A’s favour. It does not identify which named treatment has the lower rate: that requires the code mapping. It also does not, from these counts alone, establish that the underlying event rates differ. The calculation is a descriptive interim comparison, not a significance test or a final treatment-effect conclusion.
Conditions for Credible Masking
Coded summaries provide meaningful identity masking only under operational conditions. First, the code mapping must be held separately from the summaries and restricted to authorized personnel. Second, the summary itself must not contain treatment names or other direct identifiers. Third, access to the report, its discussion, and any resulting decision record must be consistent with the stated access plan. If a reviewer can readily obtain the mapping, or a meeting participant discloses it, the labels no longer conceal identity for that person.
Indirect clues also matter. A rare adverse event, a known formulation difference, or a distinctive pattern of outcomes may allow a reviewer to guess which code corresponds to which treatment. A guess is not the same as confirmed knowledge, but repeated or strongly supported guesses can weaken the intended mask. The team should consider this possibility when deciding which summaries to share and with whom. It should not promise that codes make identity inference impossible.
Before using coded summaries, the protocol and operational plan should make clear who receives them, what summaries are available, who holds the mapping, and how questions or accidental disclosures are handled. The decision process should specify how the coded information may be used. These safeguards help distinguish a planned, controlled review from an informal circulation of interim results.
Assign coded labels to the arms and restrict the code-to-treatment mapping to the designated custodian or authorized role.
Document which coded summaries the review group may receive and how those summaries relate to the planned interim decision.
Provide reports only to authorized recipients, record the review and its decision, and use established procedures for any suspected disclosure.
Consider whether the summaries or trial context could reveal identity indirectly, and avoid treating the letter labels as proof that the review remained masked.
Worked Operational Example
Worked Example: Checking a Coded Interim Report
Hypothetical setting. A trial’s interim plan allows a designated review group to see the number of participants and mean outcome in each coded arm. The group must recommend whether to continue recruitment, but the treatment mapping is held by a separate data custodian.
The report lists A: \(n=52\), mean \(=14.6\) points, and B: \(n=50\), mean \(=14.1\) points. The coded mean difference is:
The reviewer can accurately state that A’s reported mean is 0.5 points higher than B’s. If higher values are better, this is a descriptive difference in favour of A, not a justified statement that the investigational treatment is 0.5 points better. The reviewer should check that the report contains no treatment names, that access is limited as planned, and that the review’s recommendation follows the specified decision process. The reviewer should not request the mapping merely to give the difference a treatment-name direction unless the role and plan authorize that access.
This example also illustrates why a coded report is not automatically harmless. The group sees arm-separated information and may recognize a pattern. The masking arrangement protects the identity mapping; it does not erase the information that makes the adaptation review useful.
Comparisons, Diagnostics, and Limitations
Coded arm summaries occupy a middle ground between two broad arrangements. A report that combines participants across arms conceals the arm separation but may not provide the summaries needed for a decision that depends on each coded arm. A decoded report identifies the treatments and can support decisions that explicitly require treatment identity, but it exposes recipients to that identity and its comparative implications. Coded summaries retain arm separation while withholding the mapping, provided the access controls work.
The choice is not simply between “biased” and “unbiased” information. It is about what information is necessary for the planned decision and who needs it. Coded labels cannot guarantee that an adaptation will preserve the original inferential properties; that depends on the design, decision rule, and analysis plan. Nor can they prevent all operational influence: reviewers may react to a visible coded difference even when they cannot name the treatments.
Warning signs include a report that uses treatment names alongside codes, uncontrolled access to the mapping, unexplained changes in who receives interim reports, or meeting notes that convert coded patterns into treatment claims without evidence of the mapping. Another diagnostic is whether reviewers can explain the decision using the prespecified coded information rather than informal speculation. If the answer depends on a treatment identity that the group is not authorized to know, the access boundary or decision process needs attention.
Common Mistake
Correction: A and B conceal identity only if the mapping remains unavailable and other clues do not reveal it. The review still exposes separate arm summaries, including potentially informative differences. State what the coded summaries show, keep the direction tied to the labels, and do not infer which named treatment performs better without authorized identity information.
A disciplined report therefore uses statements such as “A’s mean was 0.2 units higher than B’s,” not “the investigational treatment was 0.2 units better,” unless identity is known and that statement is otherwise justified. This wording preserves what the data show without claiming more than the reviewer’s information supports. It also makes it easier to audit whether the agreed masking arrangement was maintained.
Check Your Understanding
Answer each question using coded labels unless the question explicitly supplies the treatment mapping.
- In one sentence, distinguish a treatment code from the treatment identity it represents.
- A report gives A’s mean as 6.4 units and B’s mean as 6.1 units. What is A minus B, and what can the reviewer conclude about named treatments if the mapping is withheld?
- If labels A and B are swapped, what happens to the sign and absolute value of the A-minus-B contrast?
- Name two operational conditions needed for A/B labels to conceal treatment identity.
- Why can coded arm-specific summaries still reveal comparative information even when the treatment mapping is not disclosed?
Solutions. (1) A treatment code labels a randomized arm; treatment identity names the treatment assigned to that arm. (2) \(6.4-6.1=0.3\) units, so A’s observed mean is 0.3 units higher; the reviewer cannot say which named treatment has the higher mean without the mapping. (3) The sign reverses and the absolute value is unchanged, since the swapped contrast is the negative of the original. (4) For example, restrict the mapping to authorized personnel and limit coded-report access to authorized recipients; also avoid direct treatment identifiers in the report. (5) Separate summaries permit comparison of the arms’ reported outcomes, even though the labels do not identify the treatments.